JP2014506787A - シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物 - Google Patents

シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物 Download PDF

Info

Publication number
JP2014506787A
JP2014506787A JP2013552609A JP2013552609A JP2014506787A JP 2014506787 A JP2014506787 A JP 2014506787A JP 2013552609 A JP2013552609 A JP 2013552609A JP 2013552609 A JP2013552609 A JP 2013552609A JP 2014506787 A JP2014506787 A JP 2014506787A
Authority
JP
Japan
Prior art keywords
gne
nucleic acid
cell
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013552609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506787A5 (enExample
Inventor
ダービッシュ，ダニエル
ヴァルレス―アヨウブ，ヤディラ
Original Assignee
エイチアイビーエム リサーチ グループ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイチアイビーエム リサーチ グループ，インコーポレイテッド filed Critical エイチアイビーエム リサーチ グループ，インコーポレイテッド
Publication of JP2014506787A publication Critical patent/JP2014506787A/ja
Publication of JP2014506787A5 publication Critical patent/JP2014506787A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013552609A 2011-02-01 2012-02-01 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物 Pending JP2014506787A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438585P 2011-02-01 2011-02-01
US61/438,585 2011-02-01
PCT/US2012/023536 WO2012106465A2 (en) 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017092571A Division JP2017158577A (ja) 2011-02-01 2017-05-08 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物

Publications (2)

Publication Number Publication Date
JP2014506787A true JP2014506787A (ja) 2014-03-20
JP2014506787A5 JP2014506787A5 (enExample) 2016-07-28

Family

ID=46603295

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013552609A Pending JP2014506787A (ja) 2011-02-01 2012-02-01 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物
JP2017092571A Pending JP2017158577A (ja) 2011-02-01 2017-05-08 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017092571A Pending JP2017158577A (ja) 2011-02-01 2017-05-08 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物

Country Status (9)

Country Link
US (2) US20130030040A1 (enExample)
EP (2) EP2670442A4 (enExample)
JP (2) JP2014506787A (enExample)
KR (2) KR102257741B1 (enExample)
AU (2) AU2012212162A1 (enExample)
CA (1) CA2863578C (enExample)
IL (1) IL227773B (enExample)
MX (1) MX365095B (enExample)
WO (1) WO2012106465A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12559533B2 (en) 2017-05-24 2026-02-24 Universitat Autònoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057856A1 (en) * 2012-08-22 2014-02-27 The Regents Of The Universtiy Of California Compositions and Methods For Enhancing Sialic Acid Levels In Tissue
US20150322439A1 (en) * 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
US20140256639A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
CN103088090B (zh) * 2013-03-01 2014-06-04 南京工业大学 一种n-乙酰葡萄糖胺异构酶在生产n-乙酰甘露糖胺中的应用
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
CN108285886A (zh) * 2018-01-30 2018-07-17 江南大学 重组枯草芽孢杆菌全细胞转化生产n-乙酰神经氨酸的方法
US11865165B2 (en) * 2018-09-18 2024-01-09 Daniel DARVISH GNE as a therapeutic agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070073264A1 (en) * 2003-09-26 2007-03-29 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
US20090298112A1 (en) * 2008-05-28 2009-12-03 Hibm Research Group, Inc. Mouse model and treatment of hereditary inclusion body myopathy
JP2010519184A (ja) * 2007-02-07 2010-06-03 グラダリス インク． シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
US20100184158A1 (en) * 2009-01-21 2010-07-22 James Arthur Williams DNA Plasmids with improved copy number

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
WO2001059075A1 (en) * 2000-02-08 2001-08-16 Genentech, Inc. Improved sialylation of glycoproteins
US20060218669A1 (en) * 2003-02-11 2006-09-28 Lokesh Joshi Sialylation of glycoproteins in plants
WO2008001023A1 (en) 2006-06-27 2008-01-03 Gigabeam Corporation Cellular communication system
WO2008124934A1 (en) 2007-04-17 2008-10-23 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
EP2324110A4 (en) 2008-09-09 2013-01-09 Univ California ELIMINATION OF A CONTAMINATING NON-HUMAN SIALIC ACID BY METABOLISM COMPETITION
WO2011096750A2 (en) * 2010-02-08 2011-08-11 Korea Advanced Institute Of Science And Technology Method for preparing recombinant glycoproteins with high sialic acid content

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070073264A1 (en) * 2003-09-26 2007-03-29 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
JP2010519184A (ja) * 2007-02-07 2010-06-03 グラダリス インク． シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
US20090298112A1 (en) * 2008-05-28 2009-12-03 Hibm Research Group, Inc. Mouse model and treatment of hereditary inclusion body myopathy
US20100184158A1 (en) * 2009-01-21 2010-07-22 James Arthur Williams DNA Plasmids with improved copy number

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12559533B2 (en) 2017-05-24 2026-02-24 Universitat Autònoma De Barcelona Viral expression construct comprising a fibroblast growth factor 21 (FGF21) coding sequence

Also Published As

Publication number Publication date
EP3202425A1 (en) 2017-08-09
IL227773B (en) 2021-03-25
US20140275230A1 (en) 2014-09-18
AU2017203027B2 (en) 2019-08-15
JP2017158577A (ja) 2017-09-14
MX365095B (es) 2019-05-22
AU2012212162A1 (en) 2013-08-29
IL227773A0 (en) 2013-09-30
KR102257741B1 (ko) 2021-05-28
EP2670442A2 (en) 2013-12-11
WO2012106465A2 (en) 2012-08-09
US10098969B2 (en) 2018-10-16
KR20140034150A (ko) 2014-03-19
MX2013008948A (es) 2014-02-18
US20130030040A1 (en) 2013-01-31
KR20190108178A (ko) 2019-09-23
AU2017203027A1 (en) 2017-07-20
CA2863578C (en) 2021-10-26
CA2863578A1 (en) 2012-08-09
EP2670442A4 (en) 2015-07-29
WO2012106465A3 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
AU2017203027B2 (en) Methods And Compositions For Increasing Sialic Acid Production And Treating Sialic Related Disease Conditions
TW202012628A (zh) 用於帕金森氏症治療的組成物及方法
JP2022031682A (ja) 炎症性関節疾患の治療方法
WO2011047294A1 (en) Therapeuting compositions comprising an rnai agent and a neurotrophic factor and methods of use thereof
US20240285734A1 (en) Gne as a therapeutic agent
JP2022060514A (ja) ガバペンチノイドからの干渉が減少し、ｈｇｆ異型体を発現するｄｎａコンストラクトを用いる神経病症の治療
US20220088223A1 (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
US20190374652A1 (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
WO2018213618A1 (en) Gene therapy for tuberous sclerosis
US20190234933A1 (en) Compositions and assays
WO2021028675A1 (en) Genetic construct
WO2022061292A2 (en) Therapeutic agents and uses thereof
RU2488406C1 (ru) Фармацевтическая композиция для терапии острых токсических состояний
JP2025510150A (ja) パーキンソン病の処置のための方法および組成物
WO2025049480A2 (en) Elovl2 constructs for gene therapy
Huntoon et al. Drug-and Disease-Specific Paradigms for Drug Delivery to the Central Nervous System
CA2978917C (en) Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
Pergolizzi et al. 374. Development of a Genetic Vaccine Conferring Protective Immunity Against [alpha]-Cobratoxin Following a Single Administration of an Adenovirus Vector Encoding a Modified, Non-Toxic Cobratoxin Variant
Kozlowski et al. 376. A Metabolically Responsive Insulin Transgene Delivered by AAV2/8 Pseudotyped, Self-Complementary AAV (SC-AAV2/8) Controls Glycemia in STZ-Diabetic Mice

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160601

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170801